185 related articles for article (PubMed ID: 20202796)
1. Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness.
Cunha BA
Int J Antimicrob Agents; 2010 May; 35(5):517-8. PubMed ID: 20202796
[No Abstract] [Full Text] [Related]
2. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.
Schwartz BS; Graber CJ; Diep BA; Basuino L; Perdreau-Remington F; Chambers HF
Clin Infect Dis; 2009 May; 48(10):1483-4. PubMed ID: 19374563
[No Abstract] [Full Text] [Related]
3. Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.
Hawser SP
Int J Antimicrob Agents; 2010 Apr; 35(4):414-5. PubMed ID: 20137900
[No Abstract] [Full Text] [Related]
4. Variable daptomycin susceptibility in patients receiving intravenous vancomycin for meticillin-resistant Staphylococcus aureus infections.
Golden M; Shaib W; Havill N
Int J Antimicrob Agents; 2010 Mar; 35(3):306-8. PubMed ID: 20036108
[No Abstract] [Full Text] [Related]
5. In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
Sun C; Falagas ME; Wang R; Karageorgopoulos DE; Yu X; Liu Y; Cai Y; Liang B; Song X; Liu Z
J Antibiot (Tokyo); 2011 Aug; 64(8):559-62. PubMed ID: 21772306
[TBL] [Abstract][Full Text] [Related]
6. Methicillin-resistant Staphylococcus aureus: a community concern.
Hedge DD
S D Med; 2006 Oct; 59(10):433, 435. PubMed ID: 17124921
[No Abstract] [Full Text] [Related]
7. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
Bishburg E; Bishburg K
Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin minimum inhibitory concentrations (MICs) for meticillin-resistant Staphylococcus aureus (MRSA) in Hong Kong.
Ip M; Chau SS; Lui SL; Leung E; Ling T
Int J Antimicrob Agents; 2010 Oct; 36(4):386-7. PubMed ID: 20702065
[No Abstract] [Full Text] [Related]
9. Comparing antimicrobial susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin using MicroScan (Pos Combo 3.1J) and conventional methods.
Nakashima H; Kameko M; Takahashi H; Saito H
Int J Antimicrob Agents; 2010 Sep; 36(3):291-3. PubMed ID: 20594808
[No Abstract] [Full Text] [Related]
10. Minocycline, often forgotten but preferred to trimethoprim-sulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections.
Cunha BA
Int J Antimicrob Agents; 2013 Dec; 42(6):497-9. PubMed ID: 24126085
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
Huang V; Cheung CM; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2010 Jan; 35(1):25-9. PubMed ID: 19900792
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus.
Bouza E
Clin Microbiol Infect; 2009 Dec; 15 Suppl 7():44-52. PubMed ID: 19951334
[TBL] [Abstract][Full Text] [Related]
13. Oxacillin- and cefoxitin-susceptible meticillin-resistant Staphylococcus aureus (MRSA).
Cuirolo A; Canigia LF; Gardella N; Fernández S; Gutkind G; Rosato A; Mollerach M
Int J Antimicrob Agents; 2011 Feb; 37(2):178-9. PubMed ID: 21163627
[No Abstract] [Full Text] [Related]
14. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Twilla JD; Gelfand MS; Cleveland KO; Usery JB
J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
[No Abstract] [Full Text] [Related]
15. Meticillin-resistant Staphylococcus aureus bacteraemia in Hong Kong.
You JH; Ip DN; Wong CT; Ling T; Lee N; Ip M
J Hosp Infect; 2008 Dec; 70(4):379-81. PubMed ID: 18952321
[No Abstract] [Full Text] [Related]
16. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Lawrence KR; Golik MV; Davidson L
Am J Ther; 2009; 16(4):333-8. PubMed ID: 19617720
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
Desbois AP; Gemmell CG; Coote PJ
Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptides--important treatment option for methicillin-resistant Staphylococcus aureus.
Arora S; Arora U
Indian J Med Microbiol; 2011; 29(3):313-4. PubMed ID: 21860119
[No Abstract] [Full Text] [Related]
19. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vitro resistance of Staphylococcus aureus to tetracycline, doxycycline, and minocycline with in vivo use.
Lewis SA; Altemeier WA
Chemotherapy; 1976; 22(5):319-23. PubMed ID: 947710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
